Jane Street Group, LLC Atreca, Inc. Transaction History

Jane Street Group, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.13 - $0.38 $1,482 - $4,333	11,403 New	11,403 $1,000
Q1 2022 May 17, 2022	SELL	$1.61 - $5.2 $37,607 - $121,466	-23,359 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$2.87 - $6.29 $31,822 - $69,743	11,088 Added 90.36%	23,359 $71,000
Q3 2021 Nov 16, 2021	SELL	$4.91 - $9.07 $1,698 - $3,138	-346 Reduced 2.74%	12,271 $77,000
Q2 2021 Aug 16, 2021	BUY	$7.82 - $13.8 $98,664 - $174,114	12,617 New	12,617 $108,000
Q2 2020 Aug 17, 2020	SELL	$12.52 - $23.45 $178,710 - $334,725	-14,274 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$11.4 - $27.28 $162,723 - $389,394	14,274 New	14,274 $237,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.